175 related articles for article (PubMed ID: 37727807)
1. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.
Atallah E; Welsh SJ; O'Carrigan B; Oshaughnessy A; Dolapo I; Kerr AS; Kucharczak J; Lee CYC; Crooks C; Hicks A; Chimakurthi CR; Rao A; Franks H; Patel PM; Aithal GP
JHEP Rep; 2023 Oct; 5(10):100851. PubMed ID: 37727807
[TBL] [Abstract][Full Text] [Related]
2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
3. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
6. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.
Swanson LA; Kassab I; Tsung I; Schneider BJ; Fontana RJ
Front Oncol; 2022; 12():984940. PubMed ID: 36353563
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
8. Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM.
Shi X; Zuo C; Yu L; Lao D; Li X; Xu Q; Lv Q
Front Pharmacol; 2021; 12():761167. PubMed ID: 34795591
[No Abstract] [Full Text] [Related]
9. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
10. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.
Björnsson ES; Bergmann OM; Björnsson HK; Kvaran RB; Olafsson S
Gastroenterology; 2013 Jun; 144(7):1419-25, 1425.e1-3; quiz e19-20. PubMed ID: 23419359
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
12. [Real-world study evaluating the incidence of liver damage conditions in patients with primary liver cancer using immune checkpoint inhibitor-based combination therapy].
Hu YQ; Wang N; Ran XP; Cai DC
Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):57-62. PubMed ID: 35152670
[No Abstract] [Full Text] [Related]
13. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M; Barreira-Díaz A; Salcedo MT; Callejo-Pérez A; Muñoz-Couselo E; Iranzo P; Ortiz-Velez C; Cedrés S; Díaz-Mejía N; Ruiz-Cobo JC; Morales R; Aguilar-Company J; Zamora E; Oliveira M; Sanz-Martínez MT; Viladomiu L; Martínez-Gallo M; Felip E; Buti M
Aliment Pharmacol Ther; 2024 Apr; 59(7):865-876. PubMed ID: 38327102
[TBL] [Abstract][Full Text] [Related]
14. Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies.
Panich J; Irwin C; Bissonette A; Elkhidir S; Lodhi F; Folz C; Lee J; Pulipati S; Fatima Z; Gopinath P; Blonsky R; Abboud Leon C; Kattamanchi S
J Oncol Pharm Pract; 2024 Mar; 30(2):286-294. PubMed ID: 37125423
[TBL] [Abstract][Full Text] [Related]
15. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
16. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
17. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
19. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
20. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
